Cancer clinical trials in the region Pays de la Loire

433 currently recruiting clinical trials
Region Pays de la Loire

Phase 1 / Phase 2 Lung cancer #NCT04585750 #2023-504251-27-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
KRAS G12C KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Breast cancer #NCT04585750 #2023-504251-27-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
KRAS G12C KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Endometrial cancer #NCT04585750 #2023-504251-27-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
KRAS G12C KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Lung cancer #NCT06043817
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2 Prostate cancer #NCT07226986 #2025-521859-23-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required PSMA PET Scan statuses
PSMA PET Positive
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Hormone therapy
4 recruiting sites
Novartis
Phase 1 / Phase 2 Acute leukemia #NCT04811560
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
KMT2A NPM1
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
11 recruiting sites
Janssen
Phase 1 / Phase 2 Acute leukemia #NCT04811560
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
Other mutation KMT2A NPM1 NUP214
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
11 recruiting sites
Janssen
Phase 1 / Phase 2 Acute leukemia #NCT06356922
Required histologic types
Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Hôpital universitaire de Nantes
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT05118789
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
1
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Acute leukemia #NCT04988555
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required renal function statuses
> 60 ml/min 50-60 ml/min
Required genetic anomalies
KMT2A NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.